title: Response to Pendleton et al. regarding reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States.
authors.affiliation: Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE MS-G41, Atlanta, GA 30333, USA.
authors.forename: Susan
authors.initials: S
authors.lastname: Hariri
authors.affiliation: Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, NE MS-G41, Atlanta, GA 30333, USA.
authors.forename: Lauri E
authors.initials: LE
authors.lastname: Markowitz
authors.affiliation: Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE MS-G41, Atlanta, GA 30333, USA.
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Unger
mesh_terms: D065311:Adenocarcinoma in Situ / Q000517:prevention & control*; D005260:Female; D052162:Human papillomavirus 16 / Q000302:isolation & purification*; D052161:Human papillomavirus 18 / Q000302:isolation & purification*; D006801:Humans; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D002577:Uterine Cervical Diseases / Q000517:prevention & control*; D002578:Uterine Cervical Dysplasia / Q000517:prevention & control*
chemical_list: D053918:Papillomavirus Vaccines